



US government (USG) investment in global health R&D has delivered

**\$352.8 million**  
to Pennsylvania research institutions\*

**4,300+** new jobs  
for Pennsylvania†

### Pennsylvania's top global health R&D institutions by USG funding\*

ORGANIZATION	FUNDING
Magee-Womens Research Institute & Foundation	<b>\$107.3 million</b>
University of Pennsylvania	<b>\$95.2 million</b>
University of Pittsburgh	<b>\$69.2 million</b>
Pennsylvania State University	<b>\$24.4 million</b>
Drexel University	<b>\$20.4 million</b>
Wistar Institute	<b>\$18.5 million</b>
Thomas Jefferson University	<b>\$5.8 million</b>

### Neglected diseases in Pennsylvania†

HIV diagnoses	<b>12,669</b>
Tuberculosis cases	<b>2,150</b>
Malaria cases	<b>448</b>
West Nile cases	<b>178</b>
Dengue cases	<b>133</b>

### Pennsylvania industry in global health R&D

**AstraZeneca:** Philadelphia

**Bayer:** Pittsburgh

**GSK:** Philadelphia, Upper Merion, Upper Providence

**Janssen:** Horsham, Malvern, Spring House

**Novartis:** Sinking Spring


### Global health R&D at work in the Keystone State



PATH/Scott Areman

Once HIV therapy is working, HIV can lie dormant in immune cells at low levels. It is critical to determine if this latent HIV reservoir, often containing damaged HIV, could create more virus and cause relapse if treatment is stopped. Now researchers at the University of Pittsburgh have created a test to detect this "hidden" HIV. The test is faster, easier on patients, less labor-intensive, less expensive, and more sensitive than the current gold-standard test.

### Pennsylvania's top areas of global health R&D by USG funding\*



### GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES‡

**89¢** of every dollar  
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

**200K** new US jobs

**\$33 BILLION** in US economic growth.

\*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See [www.ghtcoalition.org](http://www.ghtcoalition.org) for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See [www.ghtcoalition.org](http://www.ghtcoalition.org) for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008–2016, Tuberculosis cases 2008–2016, Malaria cases 2008–2014, West Nile virus disease cases 2008–2016, Dengue virus infection cases 2010–2016.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶ NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.